Novo Nordisk Stock Rises as New Obesity Drug Shows 22% Weight Loss
Meanwhile, those in the placebo group gained between 1.9% and 2.3%. Novo also tested an oral version of amycretin last year, showing similar weight-loss effects. Martin Lange, Novo's head of drug development, said the results reinforce amycretin's potential as a next-generation obesity treatment.
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Both companies have a dominant position in their industry and a solid financial position, but Eli Lilly seems too pricey right now. In contrast, Novo Nordisk seems rather cheap given. The ...
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Johnson & Johnson, Moderna, and Novo Nordisk.
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback